{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Austria Medical Instruments & Supplies news", "home_page_url": "https://sharemaestro.com/newsreel/at/healthcare/medical-instruments-supplies/", "feed_url": "https://sharemaestro.com/newsreel/at/healthcare/medical-instruments-supplies/feed.json", "description": "Latest Medical Instruments & Supplies company headlines from Austria, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:5971b49dee342142efd77297a630f9275b5f8928066a404b0980f77284728a39", "url": "https://finance.yahoo.com/markets/stocks/articles/stryker-13-6-3-months-174900364.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/stryker-13-6-3-months-174900364.html", "title": "Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?", "content_text": "Stryker Corporation SYK shares have risen 13.6% in the past three months, outpacing the Zacks Medical sector's 12.9% gain and the S&P 500's 1.7% advance. The move has coincided with a sharper operating recovery after a difficult first quarter. The investor question is whether improving sales, margins and production can keep supporting the stock, or whether execution demands and a richer relative valuation now make the next leg higher harder to achieve.Zacks Investment Research Image Source: Zacks Investment Research Why Stryker's Three-Month Rally Has Support Stryker's second-quarter results g", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:352a0f3761594e28dc3c1d362f7b538ee156b891d3026295e72946763c29c5ee", "url": "https://finance.yahoo.com/markets/stocks/articles/syk-worth-buying-growth-improves-174900186.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/syk-worth-buying-growth-improves-174900186.html", "title": "Is SYK Worth Buying as Growth Improves but Execution Risks Persist?", "content_text": "Stryker Corporation SYK presents a growth-versus-execution decision. Second-quarter sales and earnings improved sharply as the company recovered from its first-quarter cybersecurity disruption, while margins expanded and demand remained broad. The case is not risk-free. Cyber remediation costs, vascular supply constraints and acquisition execution still matter. For investors, the question is whether Stryker's improving fundamentals and product pipeline justify adding exposure before those operating issues are fully resolved. SYK's Growth Case Is Stronger Than Its Risk Profile Stryker delivered", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:84980dbc017c4e1caacf816c96701866d11ab80a0313de34674c2e716016b3b7", "url": "https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html", "title": "Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?", "content_text": "Stryker Corporation SYK entered the second half of 2026 with momentum restored after the March cybersecurity disruption. Second-quarter sales, earnings and margins improved as production recovered, while management narrowed its full-year outlook. The next test is execution. Stryker must keep normalizing production, convert elevated backlog into shipments and support a broad product launch cycle. Those factors will determine whether the stronger second half embedded in management's expectations materializes. Stryker's Q2 Recovery Rebuilt Momentum Stryker reported second-quarter net sales of $6.", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:94864b78b6281fa043ef47f6a4ab238ba5776c49580b8f36e8fbbb63ea9c121d", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-backs-long-133733648.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-backs-long-133733648.html", "title": "Intuitive Surgical (ISRG) Backs Long-Term Moat Amid Near-Term Volatility", "content_text": "TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the 'TCW Concentrated Large Cap Growth Fund.' A copy of the letter can be downloaded here. During the second quarter, AI monetization, a fragile Middle East ceasefire, and a Federal Reserve leadership transition were the significant events. All major indices ended higher, driven by resilient economic growth and strong corporate earnings. April marked a recovery from March lows, with the S&P 500 achieving record highs by early June, largely due to robust corporate earnings linked to AI capital spendi", "date_published": "2026-08-13T13:37:33+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:21dde91cf45aaafc1aa88dd82d517e9eb638159b94236018c60cd36d06c5b677", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNYVdwaG5sOWwzd1dXN2R4RXV5S2hnQ3RhNW5UWndfMDExRnRFd0hKN2FqQWJ1TExKVnN1cXNiMkRNQ0hadzdPclBFU0hmWExlZzRSSVY3RXpvYkFUUVl4dWZxLWRBM2lYbVp3NGlVN3B2cEVOcGthTDZPUWhJT0RjamR1akMyS2N5V1BfdWt1WWRVYUl3QUVxMjA1bzZxRng1blRDVUExMHRWMUpXcmN4N2tzMFNENm5WZ1pkemN6bkFyMWhfSGNoV1R3?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNYVdwaG5sOWwzd1dXN2R4RXV5S2hnQ3RhNW5UWndfMDExRnRFd0hKN2FqQWJ1TExKVnN1cXNiMkRNQ0hadzdPclBFU0hmWExlZzRSSVY3RXpvYkFUUVl4dWZxLWRBM2lYbVp3NGlVN3B2cEVOcGthTDZPUWhJT0RjamR1akMyS2N5V1BfdWt1WWRVYUl3QUVxMjA1bzZxRng1blRDVUExMHRWMUpXcmN4N2tzMFNENm5WZ1pkemN6bkFyMWhfSGNoV1R3?oc=5", "title": "Ottobock hebt Prognose f\u00fcr 2026 an \u2013 Aktie legt nach starken Quartalszahlen um 3 % zu", "content_text": "Ottobock hebt Prognose f\u00fcr 2026 an \u2013 Aktie legt nach starken Quartalszahlen um 3 % zu", "date_published": "2026-08-13T07:18:00+00:00", "authors": [{"name": "Investing.com Deutsch"}], "tags": ["Market update", "OBCK"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OBCK", "name": "Ottobock SE & Co. KGaA", "sentiment_url": "https://sharemaestro.com/sentiment/3e6c6319-8079-4011-884a-cd01f1cc4d5e/"}]}}, {"id": "source:c9437f7c9df7d454cc88beb6f60a9bfcb966bbe769c2cf6e3f76f9b179b4936b", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "title": "Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. See our latest analysis for Intuitive Surgical. The Q2 surprise arrives after a tough stretch for Intuitive Surgical, with the share price down 28.6% year to date and the 1 year total shareholder return ", "date_published": "2026-08-12T21:13:16+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:c6eafdfc22d548b9106fb663c201452672aac2c3d6904920bde827aebe3c9ab0", "url": "https://finance.yahoo.com/healthcare/articles/isrgs-us-procedure-growth-slows-183300794.html", "external_url": "https://finance.yahoo.com/healthcare/articles/isrgs-us-procedure-growth-slows-183300794.html", "title": "ISRG's US Procedure Growth Slows: Is ACA Headwind a Temporary Concern?", "content_text": "Intuitive Surgical ISRG has faced a moderation in U.S. procedure growth during the first half of 2026, but management's commentary suggests the slowdown is more likely a temporary demand-timing issue than evidence of a structural deterioration. U.S. da Vinci procedures grew 12% in the second quarter, down from 14% in the first quarter. da Vinci procedure growth was 17% in the fourth quarter of 2025. Management pointed to a modest adverse impact from the expiration of enhanced ACA premium subsidies. Customer feedback indicated that changes in insurance coverage and premium dynamics affected the", "date_published": "2026-08-12T18:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:2100e637b2916ecb584e6b354b330a6f85d10b7b8fa369baf89de13620dc54c4", "url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "title": "Two Years Of Growth Barely Change What You Pay For Intuitive Surgical", "content_text": "Photo by 127071 on Pixabay Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years. Intuitive Surgical (ISRG) trades at about $401.23, roughly 32% below its 52-week high and down about 15% over the past twelve months while the S&P 500 returned 22%. A fall that size usually leaves a stock cheap. This one still costs about 37.7 times its last twelve months of adjusted earnings, and what happens to that number by 2027 turns on a price the company has not set. Where The Multiple Actually Lands In 2027 Ana", "date_published": "2026-08-12T17:20:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:1a2f40c9baba16791fafa02e496aab8f277ad40842ea3d434963cc20daa39c8d", "url": "https://finance.yahoo.com/healthcare/articles/intuitive-surgical-apos-competitors-face-153642167.html", "external_url": "https://finance.yahoo.com/healthcare/articles/intuitive-surgical-apos-competitors-face-153642167.html", "title": "Intuitive Surgical's Competitors Face Challenges That Limit Long-Term Appeal, Oppenheimer Says", "content_text": "Intuitive Surgical's (ISRG) competitors face unique workflow challenges and real estate issues that impact their long-term appeal, while customized price-volume contracts complicate competitors' return on investment and its flexible per-click model allows growth opportunities in Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-12T15:36:42+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:b0259a224d0109f83881d0016c1981c58205f0f8dc852f77da3bc09682efd352", "url": "https://www.nasdaq.com/articles/intuitive-surgical-isrg-stock-has-plunged-33-2026-heres-why-one-fund-manager-remains", "external_url": "https://www.nasdaq.com/articles/intuitive-surgical-isrg-stock-has-plunged-33-2026-heres-why-one-fund-manager-remains", "title": "Intuitive Surgical (ISRG) Stock Has Plunged 33% in 2026. Here's Why One Fund Manager Remains Bullish -- and Why I Do, Too.", "content_text": "Key Points The robotic surgery specialist has over 12,000 installed systems globally. Right now, it's facing some headwinds, but it also has a lot going for it. The Baron Health Care Fund sees Intuitive Surgical as full of promise.10 stocks we like better than Intuitive Surgical \u203a If you're not familiar with Intuitive Surgical(NASDAQ: ISRG), know this: It's a massive robotic surgical systems specialist, with a recent market value topping $135 billion. That market value was quite a bit higher not so long ago, though -- because while the stock has averaged annual gains of 17% over the past decad", "date_published": "2026-08-12T13:20:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:51d09f49a249edf74240a838044ca42e1d3db275594bc2a3bd21270e54e907de", "url": "https://finance.yahoo.com/healthcare/articles/intuitive-surgical-oppenheimer-now-bullish-125931309.html", "external_url": "https://finance.yahoo.com/healthcare/articles/intuitive-surgical-oppenheimer-now-bullish-125931309.html", "title": "Intuitive Surgical: Oppenheimer now bullish, sees competition being \"crowded out\"", "content_text": "Investing.com -- Oppenheimer upgraded Intuitive Surgical to Outperform from Perform with a $500 price target in a note on Wednesday, arguing the company's strategy of \"Crowding Out Competitors\" is strategically smart. Analyst Suraj Kalia said the change reflects \"a more nuanced risk-reward assessment at these levels.\" On the positive side, the firm views U.S. competition as a \"non-factor,\" with field checks suggesting \"some unique workflow challenges for Ottava that limit long-term appeal\" and real-estate issues for Hugo. It added that Intuitive's customized price-volume contracts complicate c", "date_published": "2026-08-12T12:59:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:0f730957215724fed72c0676028ca481b671a1c667c1d0f654137bf7849ad1c6", "url": "https://finance.yahoo.com/markets/stocks/articles/invested-1000-intuitive-surgical-inc-123002658.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/invested-1000-intuitive-surgical-inc-123002658.html", "title": "If You Invested $1000 in Intuitive Surgical, Inc. 10 Years Ago, This Is How Much You'd Have Now", "content_text": "For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries. The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks. What if you'd invested in Intuitive Surgical, Inc. (ISRG) ten years ago? It may not have been easy to hold on to ISRG for all that time, but if you did, how much would your investment be worth today? Intuitive Surgical, Inc.'s Business In-Depth ", "date_published": "2026-08-12T12:30:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:93a8437a003e42bdc1cec61e325e382b08164d5e79e56bcc2ecbd8cc4c72cb21", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "title": "Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall", "content_text": "This article first appeared on GuruFocus. Intuitive Surgical (NASDAQ:ISRG) rose 0.90% premarket after Oppenheimer upgraded the robotic surgery company to Outperform from Perform with a $500 price target. The firm's case rests less on Intuitive than on its competitors: workflow integration problems for Johnson & Johnson's (NYSE:JNJ) Ottava system and physical footprint constraints for Medtronic's (NYSE:MDT) Hugo, potentially leaving the da Vinci franchise without a credible domestic challenger in the near term. Oppenheimer also pointed to the Per Click Model as a way into lower-acuity ambulator", "date_published": "2026-08-12T12:25:19+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:265e31f0158beda66b31764a5804ec15e24d1e6a508d696cb991ee80739ce24e", "url": "https://finance.yahoo.com/markets/stocks/articles/wednesday-top-wall-street-analyst-115341914.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/wednesday-top-wall-street-analyst-115341914.html", "title": "Here Are Wednesday\u2019s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck, Novo Nordisk, Okta, and More", "content_text": "Pre-Market Stock Futures: Futures are trading modestly higher as we have arrived at the day everyone on Wall Street has circled on their calendars. The July consumer price index will be released at 8:30 AM EDT, and the producer price index will be released at the same time tomorrow. Economists forecast headline CPI to rise 0.1% month-over-month and 3.4% year-over-year, with core CPI expected to increase 0.2% month-over-month and 2.5% year-over-year. One thing is for sure; if the numbers come in hot and above expectations, the stock market could see a bout of heavy selling. All of the major ind", "date_published": "2026-08-12T11:53:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:75888f862fb99d1fc168057a6c9e61e2eacc5651a5ffc663765ed1e846246f77", "url": "https://finance.yahoo.com/healthcare/articles/align-technology-prevails-china-patent-081959814.html", "external_url": "https://finance.yahoo.com/healthcare/articles/align-technology-prevails-china-patent-081959814.html", "title": "Align Technology Prevails in China Patent Infringement Action", "content_text": "Align Technology (ALGN) disclosed late Tuesday that the Jinan Intermediate People's Court in China issued a judgment in its favor, in a patent infringement action against Angelalign Technology's operating subsidiaries in China.The company provides an orthodontic treatment system Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-12T08:19:59+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ALGN"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALGN", "name": "Align Technology, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9c23ad64-d8e1-46b7-9ea6-44532a357248/"}]}}, {"id": "source:489156e89e7017d5e7f39c2ba068798752e619ef2a204d2a699011b5ae4515aa", "url": "https://finance.yahoo.com/markets/stocks/articles/recall-hit-outlook-bigger-payout-023350160.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/recall-hit-outlook-bigger-payout-023350160.html", "title": "Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)?", "content_text": "In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions share buyback program. At the same time, management issued a softer fiscal 2027 outlook tied to suspended ventilator sales after an FDA Class 1 recall and ongoing cost pressures, sharpening investor focus on how resilient ResMed's broader sleep-health and digital platform story may be. Next, we'll examine how the ventilator sales suspension and softer fiscal 2027", "date_published": "2026-08-12T02:33:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "RMD"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RMD", "name": "ResMed Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/311179d1-98ab-4046-bc62-2ac19b3faeb4/"}]}}, {"id": "source:d76aa604743ff719eac6c367311359e91cf4d28092fe9d21c23b52896def8f32", "url": "https://finance.yahoo.com/markets/stocks/articles/xray-q2-deep-dive-turnaround-140522223.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/xray-q2-deep-dive-turnaround-140522223.html", "title": "XRAY Q2 Deep Dive: Turnaround Progress Slowed by Market and Segment Headwinds", "content_text": "XRAY Q2 Deep Dive: Turnaround Progress Slowed by Market and Segment Headwinds Dental products company Dentsply Sirona (NASDAQ:XRAY) announced better-than-expected revenue in Q2 CY2026, but sales fell by 4.1% year on year to $898 million. On the other hand, the company's full-year revenue guidance of $3.55 billion at the midpoint came in 1% below analysts' estimates. Its non-GAAP profit of $0.52 per share was 50.1% above analysts' consensus estimates. Is now the time to buy XRAY? Find out in our full research report (it's free). Dentsply Sirona (XRAY) Q2 CY2026 Highlights: Revenue: $898 million", "date_published": "2026-08-11T14:05:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "XRAY"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "XRAY", "name": "DENTSPLY SIRONA Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/bad39915-018f-4b64-9213-2897286de819/"}]}}, {"id": "source:1669df33eaba3e6eee9714c010f314c05d1e8287e8ce389932ee77aaead1dfe1", "url": "https://finance.yahoo.com/markets/stocks/articles/number-one-reason-keep-buying-130939372.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/number-one-reason-keep-buying-130939372.html", "title": "The Number One Reason I Keep Buying Intuitive Surgical Now For The Long Run", "content_text": "Quick Read ISRG is down 31% YTD, but its razor-and-razorblade model now delivers 85% recurring revenue across a fleet of 11,710 da Vinci systems. MDT's Hugo and JNJ's Ottava remain early or pre-commercial, leaving ISRG's $1.73 billion quarterly instruments-and-accessories stream with no real soft-tissue competition. The dV5 supercycle is early, with only 1,700 of nearly 13,000 total systems upgraded and over 100 platform updates still planned. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Intuitive Surgical didn't make the cut. Grab the names FREE today. ", "date_published": "2026-08-11T13:09:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:622110ac6f71b3da0853e768860936c3725a5898edf3bb958499c7d35923821f", "url": "https://finance.yahoo.com/markets/stocks/articles/why-dentsply-sirona-xray-stock-041322938.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/why-dentsply-sirona-xray-stock-041322938.html", "title": "Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today", "content_text": "Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today What Happened? Shares of dental products company Dentsply Sirona (NASDAQ:XRAY) fell 6.8% in the afternoon session after the company reported second-quarter 2026 earnings, which featured a beat on profit estimates, was overshadowed by a weak full-year revenue forecast. For the quarter, revenue fell 4.1% year over year to $898 million, though this figure slightly topped Wall Street's expectations. Similarly, adjusted earnings per share of $0.52 significantly surpassed analyst estimates. However, investor sentiment appeared to sour on the co", "date_published": "2026-08-11T04:13:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "XRAY"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "XRAY", "name": "DENTSPLY SIRONA Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/bad39915-018f-4b64-9213-2897286de819/"}]}}, {"id": "source:5e24f116e94ed703b1d3d5525dad9a6595c1e7a17622c24056a09e8b6634a74d", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-just-beat-210447165.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-just-beat-210447165.html", "title": "Intuitive Surgical (ISRG) Just Beat Earnings. Is the Stock Still Worth Paying a Premium?", "content_text": "Intuitive Surgical (NASDAQ:ISRG) beat both top- and bottom-line consensus estimates in its fiscal Q2 2026 results, with revenue for the quarter growing 19% to $2.89 billion and adjusted EPS of $2.80 exceeding expectations by $0.30. Despite that, the stock plunged due to mounting concerns about slowing domestic procedure growth. Worldwide procedures, da Vinci and Ion combined, grew around 16% compared to the prior year period, with Da Vinci procedures growing approximately 15% and Ion procedures growing approximately 36%. These trends disappointed investors accustomed to the company's historica", "date_published": "2026-08-10T21:04:47+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:927f9ccad8a76401c0a14360109ddd557d24db34a3e730f18f16ee3d81dbc74b", "url": "https://finance.yahoo.com/healthcare/articles/isrg-trades-premium-p-e-144200115.html", "external_url": "https://finance.yahoo.com/healthcare/articles/isrg-trades-premium-p-e-144200115.html", "title": "ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?", "content_text": "Intuitive Surgical ISRG currently trades at a forward 12-month P/E ratio of 33.02X, above the Medical - Instruments industry's 26.53X, underscoring a valuation premium that investors must weigh against the company's growth prospects. The stock carries a Value Score of D, suggesting that shares are not particularly inexpensive despite the compression in its valuation multiple. Second-quarter 2026 results nevertheless provided a solid operating baseline. Revenues increased 19% year over year to $2.89 billion, while adjusted earnings per share (EPS) rose 28% to $2.80. Total procedures increased 1", "date_published": "2026-08-10T14:42:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:1f3a1d2d0e41f5a6089112952037dac0c453a7c78b4d75fbfa04ceabaf7c7c68", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-challenge-intuitive-124242559.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-challenge-intuitive-124242559.html", "title": "Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava\u2019s FDA Approval?", "content_text": "Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon relationships, and a rapidly expanding da Vinci 5 platform. The question for investors is not whether OTTAVA can become a viable product, but whether Johnson & Johnson (NYSE:JNJ) can convert its differ", "date_published": "2026-08-10T12:42:42+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:a7fce7bb8cf3281d6f50dd3243582755395fec6f6d49690fa201073af5e8f1d0", "url": "https://finance.yahoo.com/healthcare/articles/resmed-stock-falls-7-soft-110857107.html", "external_url": "https://finance.yahoo.com/healthcare/articles/resmed-stock-falls-7-soft-110857107.html", "title": "Resmed\u2019s stock falls by 7% on soft FY27 outlook", "content_text": "Resmed's shares fell by around 7% after the company forecast a softer than expected fiscal year 2027 (FY27) outlook due to suspended ventilator sales, ongoing macro uncertainty and inflation across electronic components and freight. Releasing its FY26 and Q4 FY26 results concurrently, the California-based sleep apnoea specialist achieved revenues of around $5.65bn in FY26, denoting a year-over-year (YoY) uptick of 10%. Meanwhile, the company reported Q4 revenues of $1.46bn, indicative of a 9% uptick YoY. Resmed's CEO, Mick Farrell, highlighted that Q4's \"strong\" results reflected \"continued mo", "date_published": "2026-08-10T11:08:57+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "RMD"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RMD", "name": "ResMed Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/311179d1-98ab-4046-bc62-2ac19b3faeb4/"}]}}, {"id": "source:d57b5b18af87a6c4c97d2c4c28d98cf6f03ef2e7928b939a0fe59ecb5ec288c0", "url": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus", "content_text": "Wall Street\u2019s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 1.92% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: TOP GAINERS: Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +15.04% Veeva Systems (VEE", "date_published": "2026-08-09T13:05:04+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:ba0d67fee27205d645a1b06dcd2e7dd93826039a4894bb643f53aaa14cfc74cf", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-stock-looks-020803082.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-stock-looks-020803082.html", "title": "Intuitive Surgical (ISRG) Stock Looks Fairly Valued Despite Its 33% Slide", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Intuitive Surgical stock has had a difficult start to 2026, with the share price down 32.6% year to date, while the Discounted Cash Flow (DCF) intrinsic value estimate now points to a level that is broadly in line with where the market is pricing the company. The year to date decline of 32.6% raises the question of whether recent weakness is now fully reflected in the share price. Management commentary around durable demand for platforms like da Vinci 5 ", "date_published": "2026-08-09T02:08:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:d4bf15b2230cbd7b388ab35f957cf11c1c7f0b4d4233cedd8aa0b69c8eb232a6", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-bylaw-changes-011205591.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-bylaw-changes-011205591.html", "title": "What Do Intuitive Surgical (ISRG) Bylaw Changes Mean For Shareholders?", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Intuitive Surgical (NasdaqGS: ISRG) has approved amendments to its bylaws, updating shareholder voting rules, nomination processes, and procedural requirements in line with recent SEC universal proxy regulations. The revised bylaws clarify how proxy solicitations are conducted and what shareholders must disclose when putting forward director nominees or other proposals. The changes affect how investors can engage with the company on governance matters and may influence future proxy conte", "date_published": "2026-08-09T01:12:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:cfa2e9eeef0f04003ff3ff3d17190b682d47e0feabacf8398b58a2ff1baa3870", "url": "https://www.nasdaq.com/articles/medtronic-vs-intuitive-surgical-which-medtech-stock-better-buy-right-now", "external_url": "https://www.nasdaq.com/articles/medtronic-vs-intuitive-surgical-which-medtech-stock-better-buy-right-now", "title": "Medtronic vs. Intuitive Surgical: Which MedTech Stock Is the Better Buy Right Now?", "content_text": "Key Points Medtronic has launched new devices that will help further improve its financial results. Intuitive Surgical's latest da Vinci system could expand its addressable market. Each stock will appeal to investors with different priorities. 10 stocks we like better than Medtronic \u203a Medtronic(NYSE: MDT) and Intuitive Surgical(NASDAQ: ISRG), two medical device leaders, haven't performed well this year. While weakness in the broader healthcare sector hasn't helped, they have both encountered company-specific issues that have contributed to their lagging the market. The good news is that there ", "date_published": "2026-08-08T21:20:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:0228fda7a01299989d2cdb3dc45402850ea86f8309b6e3713d2645b01b96fb53", "url": "https://www.nasdaq.com/articles/competition-heating-heres-why-intuitive-surgical-might-still-be-smartest-bet-medtech", "external_url": "https://www.nasdaq.com/articles/competition-heating-heres-why-intuitive-surgical-might-still-be-smartest-bet-medtech", "title": "Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech", "content_text": "Key Points Intuitive Surgical makes the da Vinci surgical robot, with 11,710 systems in use globally. Medical device competitors Medtronic and Johnson & Johnson are bringing out their own surgical robots. Intuitive Surgical's largest revenue source isn't the sale of new da Vinci systems.10 stocks we like better than Intuitive Surgical \u203a Intuitive Surgical(NASDAQ: ISRG) can be hard to own because the stock is prone to deep drawdowns. It is in a drawdown right now, with the stock down roughly 40% from its early 2025 high. Even after that drop, the price-to-earnings ratio remains lofty at 42x. Th", "date_published": "2026-08-08T16:35:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:ef97591fe7287717984e55a5dbfd4afdc7056c911aa271ab0319d5876ea6e60b", "url": "https://finance.yahoo.com/healthcare/articles/robotic-surgery-leader-intuitive-surgical-110549493.html", "external_url": "https://finance.yahoo.com/healthcare/articles/robotic-surgery-leader-intuitive-surgical-110549493.html", "title": "The Robotic Surgery Leader: Intuitive Surgical Slides Further But One Wall Street Bull Pegs Returns at 85%", "content_text": "Quick Read ISRG dropped 34% on a slower procedure growth guide, yet Q2 EPS of $2.80 crushed the $2.50 consensus for a fifth straight quarterly beat. ISRG trades 28% below Wall Street consensus while peers MDT and SYK fell less than 10% YTD, suggesting the market overcorrected on the category leader. Bernstein's $685 target implies 83% upside with the bull case hinging on the da Vinci 5 upgrade cycle mirroring the prior seven-year Xi ramp. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Intuitive Surgical didn't make the cut. Grab the names FREE today. Intui", "date_published": "2026-08-08T11:05:49+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:8275aaca16e97b6cad3acb7f5290224a6caff9add2f9688d8187f3af58028b7c", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTFBFUVVNZ0lmeFpmSmVMd01Hb001Z0p0UHdVNERYRl9udHRtb01id1hSQXZ0M2lHb2lRaC1LTzRfZTZ5cGdtTXRGNFl2X1hYb1F3MkJMTjlDRWhBeDU5MUduODR6TUtFdmJ6Qnc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiakFVX3lxTFBFUVVNZ0lmeFpmSmVMd01Hb001Z0p0UHdVNERYRl9udHRtb01id1hSQXZ0M2lHb2lRaC1LTzRfZTZ5cGdtTXRGNFl2X1hYb1F3MkJMTjlDRWhBeDU5MUduODR6TUtFdmJ6Qnc?oc=5", "title": "Intuitive Surgical Inc (ISRG) Aktienanalyse & Prognose", "content_text": "Intuitive Surgical Inc (ISRG) Aktienanalyse & Prognose", "date_published": "2026-08-07T22:08:32+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:714c26fcac389a94afcb045c3b60135acf1234cd0294cd790cdd5fef7b90f915", "url": "https://finance.yahoo.com/markets/stocks/articles/1-undervalued-dentsply-sirona-xray-201349308.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/1-undervalued-dentsply-sirona-xray-201349308.html", "title": "1% Undervalued? DENTSPLY SIRONA (XRAY) As Earnings Test Its Recovery Story", "content_text": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Earnings trigger and recent business updates DENTSPLY SIRONA (XRAY) is in focus after reporting second quarter 2026 earnings on 6 August, alongside reaffirmed full year net sales guidance and an update on long running share repurchases. The company reported quarterly sales of US$898 million compared with US$936 million a year earlier. Net income for the quarter was US$37 million compared with a net loss of US$45 million in the prior year period, with basic and diluted earnings per", "date_published": "2026-08-07T20:13:49+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "XRAY"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "XRAY", "name": "DENTSPLY SIRONA Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/bad39915-018f-4b64-9213-2897286de819/"}]}}, {"id": "source:33bffe5cf3b268d045c28d9a4c80472ffa5e6f27e9f6fed1d063bb2bc4b1c26f", "url": "https://finance.yahoo.com/markets/stocks/articles/xray-stock-falls-despite-q2-183500633.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/xray-stock-falls-despite-q2-183500633.html", "title": "XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales", "content_text": "DENTSPLY SIRONA Inc. XRAY reported second-quarter 2026 adjusted earnings per share (EPS) of 52 cents, down 1.6% year over year on an actual-value basis. The bottom line beat the Zacks Consensus Estimate of 36 cents by 44.4%. GAAP EPS in the quarter was 18 cents against loss per share of 22 cents in the prior-year quarter. XRAY's Revenue Trends and Regional Mix Revenues declined 4.1% reportedly to $898 million and 6.3% at constant currency (cc). The metric, however, beat the Zacks Consensus Estimate by 1.6%. Weakness across three dental segments weighed on sales, partly offset by Wellspect Heal", "date_published": "2026-08-07T18:35:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "XRAY"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "XRAY", "name": "DENTSPLY SIRONA Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/bad39915-018f-4b64-9213-2897286de819/"}]}}, {"id": "source:4436619822aa2399824e1618b1c1300e54414d953714bb75b3035e988907da5d", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPWkNsSVBsSmdfeHFsdnpocXZUNEktWkZYVmN6bmh1dGRDZVBHNEgtOXVtclY3SjdVdmh4UXVSVGRVZmxmbXZ2M3VTMXhxSU9yWjVfUERlZVpqSkV0SFBUSzhlZFB0NUdlT2NVeDY5Y1JHcmwyTEpLVnl2aTBzNXVhMjVjZEt5SENZZS1FWnQ5VFVvUWpIVjZBMHI1emQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPWkNsSVBsSmdfeHFsdnpocXZUNEktWkZYVmN6bmh1dGRDZVBHNEgtOXVtclY3SjdVdmh4UXVSVGRVZmxmbXZ2M3VTMXhxSU9yWjVfUERlZVpqSkV0SFBUSzhlZFB0NUdlT2NVeDY5Y1JHcmwyTEpLVnl2aTBzNXVhMjVjZEt5SENZZS1FWnQ5VFVvUWpIVjZBMHI1emQ?oc=5", "title": "Is Intuitive Surgical Stock a Buy Now After Falling 29% Year to Date?", "content_text": "Is Intuitive Surgical Stock a Buy Now After Falling 29% Year to Date?", "date_published": "2026-07-01T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Market update", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:6148f7ef9aa9af9eecc08c96c803d6465562a0413e741f230b2c45358709a7a4", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBSeFh4MEJ2aU1LX3ZaTjhGNUJxcFJVaU1Rei1DTmpsbEtWUDNsWk12MG5nNFR2bi1pc0NLdWtrcEdLWUZ0eEMtU05nd3U1TTdBbjJMZ2wwdjc1OXFNcWtjc3d0UXJicVRDaFhjYzEtNEMxZHpxZVg5bw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBSeFh4MEJ2aU1LX3ZaTjhGNUJxcFJVaU1Rei1DTmpsbEtWUDNsWk12MG5nNFR2bi1pc0NLdWtrcEdLWUZ0eEMtU05nd3U1TTdBbjJMZ2wwdjc1OXFNcWtjc3d0UXJicVRDaFhjYzEtNEMxZHpxZVg5bw?oc=5", "title": "ISRG Prognose \u2014 Kursziel f\u00fcr 2027", "content_text": "ISRG Prognose \u2014 Kursziel f\u00fcr 2027", "date_published": "2026-06-25T19:57:30+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:f6bde82796750cbdd30065f183e75405e1ce640949fd124abc7d0f01a288ae3f", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQa0VkOGRrYWh1dVdIMGZLVkUya2cySTd1aDJrdmFkNVVlYzMzdXMtUGVTS2ZUVE1iQXVEOWdfTEFVRm1OdTNUZVJ2Zlk4U1ctNzdaeU9obE4zYlBaeThsM05rYVZBWjdWcHlEeGd1ZkhmMGpQazZRc09vamFiZkd4aENFcWxFdmtmOE9NNWRMY1NJaWxjQlRlbXNSQ2ZDMDNXb2dNYTY2d18xcXNtT3dxT2NwM0FMWEZJZ0JwMnFCNTlCUVNtMFF4Vg?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQa0VkOGRrYWh1dVdIMGZLVkUya2cySTd1aDJrdmFkNVVlYzMzdXMtUGVTS2ZUVE1iQXVEOWdfTEFVRm1OdTNUZVJ2Zlk4U1ctNzdaeU9obE4zYlBaeThsM05rYVZBWjdWcHlEeGd1ZkhmMGpQazZRc09vamFiZkd4aENFcWxFdmtmOE9NNWRMY1NJaWxjQlRlbXNSQ2ZDMDNXb2dNYTY2d18xcXNtT3dxT2NwM0FMWEZJZ0JwMnFCNTlCUVNtMFF4Vg?oc=5", "title": "Intuitive Surgical Raises 2026 Procedure Guidance After a 40% EBIT Jump: Analysts Price ISRG Above $700", "content_text": "Intuitive Surgical Raises 2026 Procedure Guidance After a 40% EBIT Jump: Analysts Price ISRG Above $700", "date_published": "2026-05-07T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Guidance", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:ae83678e1f7163e1ca6c6e608758c61d7da4df0aa37cb7a9ddef5f1eb6d43036", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQT3JVRTlHbkY1eVZ6Y0c2a0tCdFNxaU1tTVVLVFFScXlaZWVScXVrYzBtOHlrWWh1aC1ySFdPN20wNnhQTWdITUd4c0xtX09TelVQZGg0TWtoVzNVd1k1empEOE8zUlMtclo1YUs3Z29nTzFNQlI3ckNsN19lQnRBU3d1ZjdEcUp5V0Z6eTVobHhaaVhCWkpKMHlhc1Vfbm1WVWp3VWhVS1hmOHAxWExjV2lqYVZxSHp2b29rN1JTMnRuOHlDQWhpYTdINk10Nnl4?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQT3JVRTlHbkY1eVZ6Y0c2a0tCdFNxaU1tTVVLVFFScXlaZWVScXVrYzBtOHlrWWh1aC1ySFdPN20wNnhQTWdITUd4c0xtX09TelVQZGg0TWtoVzNVd1k1empEOE8zUlMtclo1YUs3Z29nTzFNQlI3ckNsN19lQnRBU3d1ZjdEcUp5V0Z6eTVobHhaaVhCWkpKMHlhc1Vfbm1WVWp3VWhVS1hmOHAxWExjV2lqYVZxSHp2b29rN1JTMnRuOHlDQWhpYTdINk10Nnl4?oc=5", "title": "Intuitive Surgical \u00fcbertrifft Prognosen f\u00fcr Q1 2026, Aktie reagiert uneinheitlich", "content_text": "Intuitive Surgical \u00fcbertrifft Prognosen f\u00fcr Q1 2026, Aktie reagiert uneinheitlich", "date_published": "2026-04-21T07:00:00+00:00", "authors": [{"name": "Investing.com Deutsch"}], "tags": ["Market update", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:abad6fff9a7c2e5f086f7ca83984e0efa1bcd9b352fa233932bf5d40f30eb8fd", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQNzdiUE9TUk13OXlXSW9JTkUwbGJiaFg3OW4ybDRpLVk0N082RHcwQVVjckpmUXJHdEx3UklVYk9veVBIVVhkZmpEakt4bzc2Z0sxQlNMMEpLcjNwVzB0UGRvWHBXU2lHbnNRV0xOc2lUWEoxNzB3R1I4VnQ5VWJDSWk4TG5lNUxCNUlpUHY5YVlJMGRHRDY4?oc=5", "external_url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQNzdiUE9TUk13OXlXSW9JTkUwbGJiaFg3OW4ybDRpLVk0N082RHcwQVVjckpmUXJHdEx3UklVYk9veVBIVVhkZmpEakt4bzc2Z0sxQlNMMEpLcjNwVzB0UGRvWHBXU2lHbnNRV0xOc2lUWEoxNzB3R1I4VnQ5VWJDSWk4TG5lNUxCNUlpUHY5YVlJMGRHRDY4?oc=5", "title": "Why Intuitive Surgical Stock Has an $850 Mid-Case Target in Play", "content_text": "Why Intuitive Surgical Stock Has an $850 Mid-Case Target in Play", "date_published": "2026-04-14T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Analyst action", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:635117227cced33955d14bc22d64943c767ca5078b0d1d1af772f4550da8fb2a", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOUFc2VDhVYkNQbFN5eXdXNXM1N2Z1MmRKZVhWd2RXejcyVHp6T0VDRW40eDFaX08xM05Bd2xmakNvY0Q4SkxKcU5Kdmdsak1HVEZuYWxpOWpzU2lfcmIyY2tPdWIzOTVQMkRhZG5aSU9aNjdHVXFCSzlJbWg5VHBrbVdZTnQ2RmdsR0NaY2ItVjlWMzg?oc=5", "external_url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOUFc2VDhVYkNQbFN5eXdXNXM1N2Z1MmRKZVhWd2RXejcyVHp6T0VDRW40eDFaX08xM05Bd2xmakNvY0Q4SkxKcU5Kdmdsak1HVEZuYWxpOWpzU2lfcmIyY2tPdWIzOTVQMkRhZG5aSU9aNjdHVXFCSzlJbWg5VHBrbVdZTnQ2RmdsR0NaY2ItVjlWMzg?oc=5", "title": "Intuitive Surgical: Here\u2019s What 85% Potential Upside Looks Like", "content_text": "Intuitive Surgical: Here\u2019s What 85% Potential Upside Looks Like", "date_published": "2026-03-16T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Market update", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}, {"id": "source:6fc537c62fdd58741177294d2570005e5f18d03fd253cf8ccc3e190f9cd61747", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOWDY3TVZ3WmN4Z0IxYUVycjlHQkFBUkI1aXkxVVYxeklRRXJWT05vN0FqckNEeWFieGUtcUVXTElTczdpRndyV1JJa0Jtbnd5OEluTGY0M0Vab0dqM0RVTndpVkV3aUxacmw5a2p0Z1pMdmdrdXdXMHJ2eTZLTVpMb1hsX2YtS05CMm9xWWQwWVFWXzVV?oc=5", "external_url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOWDY3TVZ3WmN4Z0IxYUVycjlHQkFBUkI1aXkxVVYxeklRRXJWT05vN0FqckNEeWFieGUtcUVXTElTczdpRndyV1JJa0Jtbnd5OEluTGY0M0Vab0dqM0RVTndpVkV3aUxacmw5a2p0Z1pMdmdrdXdXMHJ2eTZLTVpMb1hsX2YtS05CMm9xWWQwWVFWXzVV?oc=5", "title": "Intuitive Surgical, Inc.: Konsensus der Analysten und Kursziel | 888024 | US46120E6023", "content_text": "Intuitive Surgical, Inc.: Konsensus der Analysten und Kursziel | 888024 | US46120E6023", "date_published": "2020-08-18T15:10:22+00:00", "authors": [{"name": "MarketScreener Deutschland"}], "tags": ["Market update", "ISRG"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/936f869f-aef8-4e0a-85f1-e1e4c784522c/"}]}}]}